Completed NA INTERVENTIONAL NCT00002411

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections

Interventions Didanosine Lamivudine Nelfinavir mesylate Stavudine Zidovudine

Updated 8 times since 2017 Last updated: Apr 13, 2011 Started: Mar 31, 1998 Primary completion: Sep 30, 1999 Completion: Sep 30, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002411, this NA trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 1998, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Apr 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Apr 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Charleston, United States , Charlotte, United States , Chicago, United States , Farmingdale, United States , Fort Lauderdale, United States , Fresno, United States , Galveston, United States , Houston, United States , Lebanon, United States and 17 more locations